{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-122240","form_type":"8-K","ticker":"TXMD","cik":"0000025743","company_name":"TherapeuticsMD, Inc.","filed_at":"2025-12-16T23:59:59+00:00","discovered_at":"2026-05-14T18:02:41.638147+00:00","generated_at":"2026-05-16T13:06:54.840258+00:00","sec_items":["5.07"],"event_type":"other","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"confidence":"high","headline":"TherapeuticsMD shareholders approve all proposals including share authorization increase to 640M","bullets":["Four director nominees elected: Thompson, Collins, Naughton, Roberts; each received >5.1M for votes.","Advisory say-on-pay approved: 5.16M for, 81.6K against, 8.3K abstain.","Advisory vote on frequency: 1-year chosen (5.18M votes); board adopts annual advisory vote.","Ratification of Berkowitz Pollack Brant as FY2025 auditor approved: 6.77M for, 42.2K against.","Amendment to increase authorized common shares to 640M approved: 6.27M for, 548.9K against."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-122240","json":"https://secwatch.observer/filing/0001213900-25-122240.json","markdown":"https://secwatch.observer/filing/0001213900-25-122240.md","text":"https://secwatch.observer/filing/0001213900-25-122240.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/25743/000121390025122240/0001213900-25-122240-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/25743/000121390025122240/ea0269797-8k_therap.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T13:06:54.840258+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}